Drugs / BURAPITANT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00564226 | Nov 2007 → Feb 2009 | overactive bladder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00174798 | May 2005 → May 2006 | overactive bladder | Sanofi | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BURAPITANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544947 ↗ |
| Known as | SSR-240600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544947 ↗ |
| Known as | SSR240600C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00564226 ↗ |
| Action | Inhibit | “Neurokinin 1 receptor antagonist” CHEMBL3544947 ↗ |
| Modality | Small molecule | — CHEMBL3544947 ↗ |
| Route | Oral | “oral administration” NCT00564226 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL3544947 ↗ |